Since its inception in 2014, Roivant has achieved the following critical milestones in support of its vision: built over 20 Vants; 12 consecutive positive Phase 3 trials; 8 FDA approvals; 5 successful IPOs; >$6B in capital raised; >$10B in global pharma partnerships and proceeds; and continued pipeline expansion across various modalities and therapeutic areas through in-licensing and acquisition of novel product candidates and technology platforms. Currently pursuing an undergraduate degree in the life sciences, business, economics, or a related quantitative field (e.g., Biology, Chemistry, Biochemistry, Economics, Finance, Data Science, Public Health), with demonstrated interest or experience in healthcare, biotech, or the life sciences.